Drug Profile

Sumatriptan needle-free injectable - Glide/Endo, Inc.

Alternative Names: Glide sumatriptan; GP-01; Sumatriptan SDI

Latest Information Update: 01 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Glide Pharma
Developer Endo, Inc.; Glide Technologies
Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
Mechanism of Action Serotonin 1D receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Migraine

Most Recent Events

23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
17 Mar 2011 Phase-II clinical trials in Migraine in Canada (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com